Chugai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

13.83

P/S

4.58

EPS

235.38

Div Yield, %

—

Shrs. gr., 5y

0.01%

Rev. gr., 5y

11.27%

Revenues

1.17t

+5.33%

Net income

387.32b

+19.00%

CFO

447.60b

+9.19%

Dividend

Dec 28, 20230.12297 USD/sh

Earnings

Apr 22, 2025

Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

URL

https://www.chugai-pharm.co.jp/

IPO date

Mar 03, 1956

Employees

7,771

Domiciled in

Incorporated in

Valuation

Order:

Title JPY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title JPY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	1,170,611,000 5.33%	1,111,367,000 -11.79%	1,259,946,000 26.02%
Cost of revenue	520,849,000	700,754,000	726,637,000
Unusual Expense (Income)
NOPBT	649,762,000	410,613,000	533,309,000
NOPBT Margin	55.51%	36.95%	42.33%
Operating Taxes	155,717,000	118,349,000	156,737,000
Tax Rate	23.97%	28.82%	29.39%
NOPAT	494,045,000	292,264,000	376,572,000
Net income	387,317,000 19.00%	325,472,000 -13.08%	374,429,000 23.58%
Dividends	(133,249,000)	(131,594,000)	(138,220,000)
Dividend yield	1.16%	1.50%	2.49%
Proceeds from repurchase of equity	(10,000)	212,000	236,000
BB yield	0.00%	0.00%	0.00%
Debt
Debt current			6,434,000
Long-term debt		6,480,000	7,245,000
Deferred revenue		378,000	430,000
Other long-term liabilities	16,517,000	12,585,000	14,555,000
Net debt	(996,345,000)	(733,756,000)	(210,327,000)
Cash flow
Cash from operating activities	447,600,000	409,925,000	244,112,000
CAPEX	(50,925,000)	(71,948,000)	(71,239,000)
Cash from investing activities	(227,365,000)	(37,290,000)	(145,994,000)
Cash from financing activities	(141,006,000)	(139,331,000)	(145,641,000)
FCF	533,876,000	294,323,000	196,713,000
Balance
Cash	996,345,000	738,982,000	503,107,000
Long term investments		1,254,000	(279,101,000)
Excess cash	937,814,450	684,667,650	161,008,700
Stockholders' equity	1,831,603,000	1,556,225,000	1,355,582,000
Invested Capital	980,201,550	953,875,350	1,185,824,300
ROIC	51.09%	27.32%	36.04%
ROCE	33.88%	24.97%	39.39%
EV
Common stock shares outstanding	1,645,637	1,645,499	1,645,338
Price	6,999.00 31.02%	5,342.00 58.61%	3,368.00 -9.83%
Market cap	11,517,814,392 31.03%	8,790,255,567 58.63%	5,541,498,155 -9.82%
EV	10,521,469,392	8,056,499,567	5,331,171,155
EBITDA	681,427,000	442,353,000	564,743,000
EV/EBITDA	15.44	18.21	9.44
Interest			61,000
Interest/NOPBT			0.01%